<DOC>
	<DOCNO>NCT01716039</DOCNO>
	<brief_summary>Assess body 's reaction dose-response relationship adalimumab/Methotrexate interaction subject moderately severely active ulcerative colitis .</brief_summary>
	<brief_title>Pharmacokinetics Adalimumab With Methotrexate Treatment Patients With Ulcerative Colitis ( UC )</brief_title>
	<detailed_description>Assess Pharmacokinetic dose-response relationship adalimumab/Methotrexate interaction subject moderately severely active UC .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Male nonpregnant , nonlactating female . Females child bear potential must negative serum pregnancy test prior randomization , must use hormonal ( oral , implantable injectable ) barrier method birth control throughout study . Females unable bear child must documentation source record ( i.e. , tubal ligation , hysterectomy , postmenopausal [ define minimum one year since last menstrual period ] ) . Diagnosis UC confirm establish criterion , regardless disease duration . Moderate severely active UC , define modify Mayo Score ≥6 , confirm endoscopic activity central reader ( Mayo endoscopic subscore ≥2 ) . Require initiation adalimumab induction remission . Ability subject swallow study drug capsule . Ability subject participate fully aspects clinical trial . Written informed consent must obtain document . Prior treatment TNF antagonist biological therapy . Prior treatment MTX . Disease limit rectum ( proctitis ) . Documented presence antibody adalimumab . Contraindication antiTNF MTX therapy . Contraindication endoscopy . Ostomy . Planned surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Moderately severely active Ulcerative Colitis</keyword>
</DOC>